RT Journal Article
SR Electronic
T1 Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5219
OP 5223
DO 10.21873/anticanres.13719
VO 39
IS 9
A1 FONTANA, VINCENZO
A1 PISTILLO, MARIA PIA
A1 VIGANI, ANTONELLA
A1 CANESSA, PIER ALDO
A1 BERISSO, GIOVANNI
A1 GIANNONI, UGO
A1 FERRO, PAOLA
A1 FRANCESCHINI, MARIA CRISTIANA
A1 CAROSIO, ROBERTA
A1 TONARELLI, MARIKA
A1 ROSSI, CRISTIANA
A1 DESSANTI, PAOLO
A1 RONCELLA, SILVIO
YR 2019
UL http://ar.iiarjournals.org/content/39/9/5219.abstract
AB Aim: This study evaluated the prognostic value of soluble mesothelin-related protein (SMRP) levels in pleural effusions (PE) from patients with pleural mesothelioma (MPM). Patients and Methods: SMRP level in PE was tested using an enzyme-linked immunosorbent assay (ELISA) in 109 patients with MPM at diagnosis before any treatment. The Kaplan–Meier method and the Cox regression were applied to compare overall survival probabilities across tertile categories of SMRP level. Results: No significant differences in Kaplan–Meier overall survival probabilities among the SMRP categories were found. A statistically non-significant trend for increased death rate ratio (RR) was computed (p=0.327) when the higher (>46.5 nM, RR=1.38) and intermediate (8.5-46.5 nM, RR=1.18) SMRP categories were compared to the lower category (<8.5 nM, RR=1.00). Cox regression modelling including a restricted cubic spline showed a moderately rising non-linear trend in death rate. Conclusion: The SMRP level in PE does not appear to have prognostic significance and its detection is not recommended in routine clinical management of patients with MPM.